- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04952779
Regulatory Post Marketing Surveillance (rPMS) Study of Xultophy® (Insulin Degludec/Liraglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea
A Multi-centre, Prospective, Open-label, Single-arm, Non-interventional, Regulatory Post Marketing Surveillance (rPMS) Study of Xultophy® (Insulin Degludec / Liraglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Locations
-
-
-
Busan, Korea, Republic of, 47354
- Novo Nordisk Investigational Site
-
Busan, Korea, Republic of, 47392
- Novo Nordisk Investigational Site
-
Busan, Korea, Republic of, 49267
- Novo Nordisk Investigational Site
-
Daegu, Korea, Republic of, 42601
- Novo Nordisk Investigational Site
-
Daejeon, Korea, Republic of, 302-120
- Novo Nordisk Investigational Site
-
Daejeon, Korea, Republic of, 35220
- Novo Nordisk Investigational Site
-
Daejeon, Korea, Republic of, 361-711
- Novo Nordisk Investigational Site
-
Goyang, Korea, Republic of, 10326
- Novo Nordisk Investigational Site
-
Gyeonggi-do, Korea, Republic of, 13620
- Novo Nordisk Investigational Site
-
Gyeonggi-do, Korea, Republic of, 14754
- Novo Nordisk Investigational Site
-
Gyeonggi-do, Korea, Republic of, 16499
- Novo Nordisk Investigational Site
-
Gyeongsangnam-do, Korea, Republic of, 52727
- Novo Nordisk Investigational Site
-
Hwasung-si, Korea, Republic of, 18450
- Novo Nordisk Investigational Site
-
Incheon, Korea, Republic of, 22332
- Novo Nordisk Investigational Site
-
Jeonju, Korea, Republic of, 561-712
- Novo Nordisk Investigational Site
-
Seoul, Korea, Republic of, 01450
- Novo Nordisk Investigational Site
-
Seoul, Korea, Republic of, 04058
- Novo Nordisk Investigational Site
-
Seoul, Korea, Republic of, 130711
- Novo Nordisk Investigational Site
-
Seoul, Korea, Republic of, 06591
- Novo Nordisk Investigational Site
-
Seoul, Korea, Republic of, 04551
- Novo Nordisk Investigational Site
-
Seoul, Korea, Republic of, 01830
- Novo Nordisk Investigational Site
-
Uijeongbu, Korea, Republic of, 11759
- Novo Nordisk Investigational Site
-
Ulsan, Korea, Republic of, 682-060
- Novo Nordisk Investigational Site
-
Ulsan, Korea, Republic of, 44686
- Novo Nordisk Investigational Site
-
-
Cheongsa-ro, Seo-gu
-
Daejeon, Cheongsa-ro, Seo-gu, Korea, Republic of, 35220
- Novo Nordisk Investigational Site
-
-
Chungcheongnam-do
-
Cheonan, Chungcheongnam-do, Korea, Republic of, 31151
- Novo Nordisk Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- The decision to initiate treatment with commercially available Xultophy® has been made by the participant/Legally Acceptable Representative (LAR) and the study doctor before and independently from the decision to include the participant in this study.
- Informed consent obtained before any study related activities. Study related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
- Male or female, age 19 years or older at the time of signing informed consent form.
- Participants diagnosed (clinically) with T2DM and who is scheduled to start treatment with Xultophy® based on the clinical judgment of their treating physician as specified in the approved Korean-Prescribing information (local label).
Exclusion Criteria:
- Participants who are or have previously been on Xultophy® therapy.
- Known or suspected hypersensitivity to Xultophy® (the active substance or any of the excipients).
- Previous participation in this study. Participation is defined as having given informed consent in this study.
- Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Xultophy®
Korean adults with type 2 diabetes mellitus (T2DM) initiating Xultophy® under routine clinical practice and according to approved label in Korea.
|
Xultophy® is a fixed ratio combination of the long-acting basal insulin, insulin degludec, and the glucagon-like peptide 1 receptor agonist (GLP-1 RA), liraglutide, administered under the skin. Patients will be treated according to routine clinical practice at the discretion of the treating physician according to the label approved by MFDS. The assignment of the patient to Xultophy® is not decided in advance by the protocol but falls within current practice and the prescription of Xultophy® is clearly separated from the decision to include the patient in the study.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Adverse Events (AEs) by preferred term
Time Frame: baseline (Visit1, 0 week) to 26 weeks
|
Count of events
|
baseline (Visit1, 0 week) to 26 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Level 3 hypoglycaemia (severe) or level 2 hypoglycaemia
Time Frame: Visit1 (0 week) to 26 weeks
|
Plasma Glucose (PG) less than 54 mg/dL (3.0 mmol/L)
|
Visit1 (0 week) to 26 weeks
|
Change in body weight
Time Frame: Visit 1 (0 week), Visit 3 (13 weeks)
|
Kilograms
|
Visit 1 (0 week), Visit 3 (13 weeks)
|
Change in body weight
Time Frame: Visit 1 (0 week), Visit 4 (26 weeks)
|
kilograms
|
Visit 1 (0 week), Visit 4 (26 weeks)
|
Change of Xultophy® dose
Time Frame: Visit 1 (0 week), 13 weeks (Visit 3)
|
Units
|
Visit 1 (0 week), 13 weeks (Visit 3)
|
Change of Xultophy® dose
Time Frame: Visit (0 week), Visit 4 (26 weeks)
|
Units
|
Visit (0 week), Visit 4 (26 weeks)
|
Change in Glycosylated Haemoglobin (HbA1c)
Time Frame: Visit 1 (0 week), Visit 3 (13 weeks)
|
Percentage
|
Visit 1 (0 week), Visit 3 (13 weeks)
|
Change in HbA1c
Time Frame: Visit 1 (0 week), Visit 4 (26 weeks)
|
Percentage
|
Visit 1 (0 week), Visit 4 (26 weeks)
|
Individuals achieving HbA1c target less than 7.0 %
Time Frame: Visit 1 (0 week), Visit 3 (13 weeks)
|
Percentage
|
Visit 1 (0 week), Visit 3 (13 weeks)
|
Individuals achieving HbA1c target less than 7.0 %
Time Frame: Visit 1 (0 week), Visit 4 (26 weeks)
|
Percentage
|
Visit 1 (0 week), Visit 4 (26 weeks)
|
Change in Fasting Blood Glucose/Plasma Glucose (FBG/FPG)
Time Frame: Visit 1 (0 week), Visit 3 (13 weeks)
|
mg/dl
|
Visit 1 (0 week), Visit 3 (13 weeks)
|
Change in Fasting Blood Glucose/Plasma Glucose (FBG/FPG)
Time Frame: Visit 1 (0 week), Visit 4 (26 weeks)
|
mg/dl
|
Visit 1 (0 week), Visit 4 (26 weeks)
|
Change in Post Prandial Blood/Plasma Glucose (PPBG/PPPG)
Time Frame: Visit 1 (0 week), Visit 3 (13 weeks)
|
mg/dl
|
Visit 1 (0 week), Visit 3 (13 weeks)
|
Change in Post Prandial Blood/Plasma Glucose (PPBG/PPPG)
Time Frame: Visit 1 (0 week), Visit 3 (26 weeks)
|
mg/dl
|
Visit 1 (0 week), Visit 3 (26 weeks)
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Clinical Transparency dept. 1452, Novo Nordisk A/S
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Endocrine System Diseases
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Incretins
- Insulin
- Insulin, Globin Zinc
- Insulin, Long-Acting
- Liraglutide
- Xultophy
Other Study ID Numbers
- NN9068-4445
- 1111-1211-7084 (Other Identifier: World Health Organization)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
Diabetes Foundation, IndiaNational Diabetes Obesity and Cholesterol FoundationRecruitingType 2 Diabetes Mellitus With ComplicationIndia
Clinical Trials on Xultophy® (insulin degludec/liraglutide)
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2 | DiabetesUnited States, India, Italy, Mexico, Russian Federation, Slovakia, Spain, Canada, Taiwan, Finland, Hungary, Malaysia, South Africa, United Kingdom, Germany, Australia, Thailand, Ireland, Puerto Rico, Singapore
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2 | DiabetesChina
-
Novo Nordisk A/SCompleted
-
Novo Nordisk A/SCompletedHealthy | DiabetesGermany
-
University of PalermoCompleted
-
Novo Nordisk A/SCompleted
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2 | DiabetesJapan
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2 | DiabetesHong Kong, China
-
Novo Nordisk A/SCompleted